Multiresistant tuberculosis

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

Extensively drug-resistant TB; MDR-TB; Tuberculosis multiresistant; XDR-TB

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

According to the definition of the WHO, multidrug-resistant tuberculosis (MDR-TB) is present when the mycobacterium tuberculosis pathogens do not respond to the two most effective anti-tuberculosis drugs, isoniazid and rifampicin(Dheda K et al. (2019).

Extremely resistant tuberculosis, XDR-TB (extensively drug-resistant TB), is a special form of multi-resistant tuberculosis. XDR-TB is even more difficult to treat than MDR-TB, because in addition to a non-response to isoniazid and rifampicin, there is also additional resistance - to fluoroquinolones(levofloxacin or moxifloxacin) and at least one parenteral antibiotic with amikacin or capreomycin or kanamycin (all second-line antibiotics) (Bahuguna A et al. 2020; Ignatius EH et al. 2019).

Note(s)This section has been translated automatically.

According to WHO, cases of XDR-TB have been reported from 117 countries so far. According to the TB Alliance, the cure rates for non-resistant TB are 83%, for MDR-TB 54% and for XDR 30%.

LiteratureThis section has been translated automatically.

  1. Bahuguna A et al (2020) An overview of new antitubercular drugs, drug candidates, and their targets. Med Res Rev 40:263-292.
  2. Dheda K et al (2019) The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respir Med 7:820-826.
  3. Ignatius EH et al (2019) New Drugs for the Treatment of Tuberculosis. Clin Chest Med 40: 811-827. doi: 10.1016/j.ccm.2019.08.001.

Authors

Last updated on: 29.10.2020